Neutron Analysis of Glaucoma Drugs Could Help Aggressive Cancer Drug Design

News   Feb 13, 2018 | Original story from Oak Ridge National Laboratory

 
Neutron Analysis of Glaucoma Drugs Could Help Aggressive Cancer Drug Design

This image shows the active site of hCA II. The active site is flanked by hydrophilic (violet) and hydrophobic (green) binding pockets that can be used to design specific drugs targeting cancer-associated hCAs. Five clinical drugs are shown superimposed in the hCA II active site, based on room-temperature neutron structures. Credit: (ORNL/Andrey Kovalevsky)

 
 
 

RELATED ARTICLES

Putting the Brain at the Center of Anesthesiology

News

Emery N. Brown explains how statistics and neuroscience improve anesthesiology at the American Association for the Advancement of Science's annual meeting.

READ MORE

Computational Model Underlines Need for Personalised Approach to Sepsis

News

A computational model of the human immune system has enabled researchers to explore the challenges of tackling sepsis.

READ MORE

Drug Transport Gene May Explain Why Ovarian Cancer Patients React Differently to Chemotherapy

News

A gene which produces a protein that transports drugs in and out of cells may explain why some women treated with chemo have serious side effects.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Cancer Research Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE